

About RHT Health Trust

RHT Health Trust ("RHT") is a registered Business Trust with an investment mandate to invest principally in medical and healthcare assets and services, in Asia, Australasia and emerging markets in the rest of the world. RHT may also develop medical and healthcare assets. It is expected that the medical services will be provided directly by RHT or in collaboration with third parties.

Key Information on the Initial Portfolio

RHT's Portfolio as of 30 June 2016 comprises twelve RHT Clinical Establishments, four Greenfield Clinical Establishments and two Operating Hospitals located across India.

Clinical Establishments

Amritsar
Bengaluru, BG Road
Chennai, Malar
Faridabad
Gurgaon
Jaipur
Kolkata
Mohali (including land acquired as an extension)
Mumbai, Kalyan
Mumbai, Mulund
New Delhi, Shalimar Bagh
Noida

Greenfield Clinical Establishments

Ludhiana Chennai Hyderabad Greater Noida

Operating Hospitals

Bengaluru, Nagarbhavi Bengaluru, Rajajinagar

Distribution policy

RHT's policy is to distribute at least 90.0% of its distributable income on a semi-annual basis, for every six-month period ending 30 September and 31 March. For the year ending 31 March 2017, the RHT Health Trust Manager Pte. Ltd ("Trustee-Manager") intends to distribute 95% of its distributable income. This policy will not apply to the proposed special distribution, mentioned in the announcement titled "Proposed Disposal And Related Documents" dated 8th July 2016. It is intended that the entire net proceeds from the Proposed Disposal And Related Documents be distributed.



Table of Contents

1	Unaudited Results for the quarter ended 30 June 2016
1(a)	Consolidated Statement of Comprehensive Income and Distributable Income Statement
1(b)(i)	Balance Sheets
1(b)(ii)	Group's Borrowings and Debt Securities
1(c)	Consolidated Cash Flow Statement
1(d)(i)	Statement of Changes in Unitholders' Funds
1(d)(ii)	Units in issue
2	Audit
3	Auditors' Report
4	Accounting Policies
5	Changes in Accounting Policies
6	Earnings Per unit ("EPU") and Distribution per unit ("DPU")
7	Net Asset Value
8	Review of Group Performance
9	Variance from Forecast
10	Market and Industry Information
11	Information on Distribution
12	Distribution
13	Interested Person Transactions
14	Confirmation by Board
15	Confirmation by Issuer



1 Unaudited Results for the quarter ended 30 June 2016

The Board of Directors of RHT Health Trust Manager Pte. Ltd. announces the following unaudited results of RHT and its subsidiary companies ("RHT Group") for the quarter ended 30 June 2016.

1(a) Consolidated Statement of Comprehensive Income and Distributable Income Statement

	Notes	FY 17 Q1	FY 16 Q1	Var
		S\$'000	S\$'000	
Revenue:				
Service fee	1	31,991	31,971	0%
Hospital income	2	2,532	2,446	4%
Other income	3	868	952	-9%
Total revenue		35,391	35,369	0%
Service fee and hospital expenses:				
Medical consumables	4	(2,429)	(2,344)	4%
Employee benefits expense*	5	(892)	(834)	7%
Doctor charges*	6	(2,302)	(2,309)	0%
Depreciation and amortisation	7	(3,913)	(3,891)	1%
Other service fee expenses*	8	(3,941)	(4,005)	-2%
Hospital expenses*	2	(2,114)	(1,912)	11%
Total service fee and hospital expenses		(15,591)	(15,295)	2%
		444	400	
Finance Income		441	136	n.m
Finance Expenses	9	(2,333)	(1,442)	62%
Trustee-Manager Fee	10	(1,652)	(1,612)	2%
Other Trust Expenses*	11	(332)	(665)	-50%
Foreign exchange loss	12	(706)	(5,405)	-87%
Total expenses		(20,173)	(24,283)	-17%
Profit before changes in fair value of financial				
derivatives		15,218	11,086	37%
	40		5.040	
Fair value gain on financial derivatives	13	231	5,340	n.m
Profit before taxes		15,449	16,426	-6%
Income tax expense	14	(4,783)	(4,131)	16%
Net profit for the period attributable to				
unitholders of the Trust		10,666	12,295	-13%
Other comprehensive income				
Items that may be reclassified subsequently to				
profit or loss				
Foreign currency translation		(16,578)	(31,366)	n.m
Other comprehensive income for the period,		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	\- ,/	
net of tax		(16,578)	(31,366)	n.m
			, , ,	
Total comprehensive income for the period				
attributable to unitholders of the Trust		(5,912)	(19,071)	n.m

^{*}Prior quarter's amounts have been reclassified to conform to current quarter's presentation.



1(a) Consolidated Statement of Comprehensive Income and Distributable Income Statement (Cont'd)

Reconciliation to Unitholders Distributable Income

Net profit for the period attributable to unitholders of the Trust	Notes	FY 17 Q1 S\$'000 10,666	FY 16 Q1 S\$'000 12,295
Distribution adjustments:			
Impact of non-cash straight-lining		(854)	(1,112)
Technology renewal fee		(167)	(174)
Depreciation and amortisation		3,913	3,891
Amortisation of debt arrangement fee		-	151
Trustee-Manager fees payable in units		826	806
Deferred tax	14	555	1,033
Foreign exchange differences	15	512	(1,168)
Capital expenditure	16	(314)	(276)
Unrealised gain on financial asset		(3)	(3)
Total distributable income attributable to unitholders of the Trust*		15,134	15,443

^{*95%} of Distributable Income for FY17 Q1 will be distributed

Notes to Consolidated Statement of Comprehensive Income and Distributable Income Statement

 The service fee is the aggregate of the base and variable service fee for the provision of the Clinical Establishment services, including but not limited to the out-patient department services (OPD) and the radio diagnostic services (RDS).

INR mn	FY17 Q1	FY16 Q1	Variance
Base Fee	1,039	1,013	2.6%
Variable Fee	500	451	10.9%

The service fees compared to corresponding quarter in INR terms are higher due to the contractual 3% increase in base fee and higher variable fee as a result of higher operating revenue recorded by the operator. The higher operating revenue was a result of higher occupancy and higher ARPOB contributed by the increase in major surgeries such as heart and liver transplant, joint replacement and neuro.

2. RHT has 2 Operating Hospitals, Bengaluru, Rajajinagar Operating Hospital and the Bengaluru, Nagarbhavi Operating Hospital. The hospital income and expense arises solely from the provision of medical services at these hospitals.

The higher hospital income for the quarter is due to increase in number of major surgeries for certain medical programs.

- 3. Other income includes lease income from pharmacy, cafeteria, bookshop, automated teller machines and other amenities in the Clinical Establishments of the Group. In the corresponding period, there was a profit being recognised on sale of asset. There is no such profit in current quarter.
- 4. The increase in medical consumables for the quarter is in line with increase in variable service fee.
- 5. The increase in employee benefits expense for the quarter is a result of increase in salaries on account of annual appraisals and additional headcounts for the project team and respective clinical establishment.



1(a) Consolidated Statement of Comprehensive Income and Distribution Statement (Cont'd)

Notes to Consolidated Statement of Comprehensive Income and Distribution Statement (Cont'd)

- 6. Doctors' charges in INR terms is higher against corresponding quarter which is in line with the increase in variable fee excluding the additional cost arising from the initiative to expand the out-patient department capacity in various Clinical Establishments in the corresponding quarter.
- 7. Depreciation and amortisation is higher for the quarter due to the increase in fair value of assets at the end of 31 March 2016.
- 8. Other service fee expenses mainly consist of housekeeping costs, security costs, power and fuel expenses, annual equipment maintenance charges for both medical and non-medical equipment owned by RHT Group, rent, property taxes and insurance, as well as administrative expenses.

The increase in other service fee expenses for the quarter in INR terms is mainly due to higher housekeeping and security cost resulting from inflationary increase and increase in activities in the clinical establishments.

- 9. The higher finance expense for the quarter corresponds with a fixed interest rate on the bonds issued to replace a floating rate debt. Furthermore, the Group utilised a \$30 million facility during the third quarter of last financial year to fund the acquisition of land and expansion projects which contributed to the higher finance expenses as well.
- The Trustee-Manager fee for the quarter is higher due to higher asset value offset by the lower distributable income.
- 11. The higher other trust expense in FY16 Q1 was a result of expenses in connection with the professional fees in connection with the issuance of the first series of notes under the medium term note programme.
- 12. The foreign exchange differences are on the account of:
 - (i) unrealised differences from interest receivables denominated in INR; and
 - (ii) realised differences from the settlement of forward contracts and interest received.

The foreign exchange loss for the quarter arose from the depreciation of INR against SGD on the INR denominated interest receivables and realised loss from the settlement of forward contracts.

13. RHT Group has entered into forward contracts to manage its Indian Rupees denominated cash flows from India. The forward contracts are carried at fair value. The fair value gain recognised in current quarter is a result of the appreciation of the expected INR against SGD at the time of settlement compared to the trailing quarter.



1(a) Consolidated Statement of Comprehensive Income and Distribution Statement (Cont'd)

Notes to Consolidated Statement of Comprehensive Income and Distribution Statement (Cont'd)

14. This relates to withholding tax expense on the offshore interest payment from the India subsidiary companies to the Singapore holding company, corporate tax in an Indian subsidiary and deferred tax in certain India subsidiary companies for the respective periods.

	FY 17 Q1	FY 16 Q1
Current tax	4,228	3,098
Deferred tax	555	1,033

The higher current tax in current quarter is due to corporate tax expense in an Indian subsidiary.

The deferred tax expense for current quarter is lower as a result of the reversal of deferred tax liability.

- 15. Included in foreign exchange differences are
 (i) adjustments for the distributable income based on the average forward contracted INR/SGD rate against INR/SGD for the translation of the statement of comprehensive income, (ii) changes in fair value on financial derivatives and; (iii) foreign exchange differences recorded in the statement of comprehensive income.
- 16. This relates to operating cash flow being used to partially fund capital expenditure.



1(b)(i) Balance Sheets

		Group		Tre	ust
	Notes	30 June 2016	31 March 2016	30 June 2016	31 March 2016
		S\$'000	S\$'000	S\$'000	S\$'000
ASSETS					
Non-current assets					
Intangible assets	1	125,064	127,986	-	-
Property, plant and equipment	2	828,455	844,851	-	=
Invesment in subsidiary		-	-	12,634	12,634
Loan to a subsidiary		-	-	469,534	478,922
Financial assets	3	36,749	36,047	-	-
Deferred tax assets	4	5,708	6,011	-	-
Other assets	5	25,122	24,783	-	-
Total non-current assets		1,021,098	1,039,678	482,168	491,556
Current assets					
Inventories		128	130	-	=
Financial assets	3	77,323	79,783	17,925	49,090
Trade receivables	6	10,944	25,340	-	-
Other assets		1,588	983	304	65
Derivative financial instruments	9	1,122	891	-	=
Cash and bank balances		8,968	5,831	36	344
Total current assets		100,073	112,958	18,265	49,499
Total assets		1,121,171	1,152,636	500,433	541,055
LIABILITIES					
Non-current liabilities					
Loans and borrowings		104,854	166,598	60,000	60,000
Other liabilities	8	2,897	3,710	-	-
Deferred tax liabilities	7	140,981	143,233		-
Total non-current liabilities		248,732	313,541	60,000	60,000
Current liabilities		00.740	2 420	4 000	505
Loans and borrowings		66,749	3,438	1,200	525
Trade and other payables	0	7,582	6,032	_	- 0.400
Other liabilities	8	93,232	90,017	2,670	3,103
Total current liabilities Total liabilities		167,563	99,487	3,870 63,870	3,628 63,628
Total habilities		416,295	413,028	63,870	03,020
Net assets		704,876	739,608	436,563	477,427
Unitholders' funds					
Represented by:					
Units in issue (net of unit issue cost)		512,057	510,399	512,057	510,399
Capital reserve	10	210,216	210,216	-	-
Foreign currency translation reserve		(99,047)	(82,469)	-	-
Revaluation reserve		141,171	142,911	-	-
Other reserves	11	33	33	-	-
Accumulated losses		(59,554)	(41,482)	(75,494)	(32,972)
Total unitholders' fund		704,876	739,608	436,563	477,427



1(b)(i) Balance Sheets (Cont'd)

Notes to Balance Sheets

1. Intangible assets

Intangible assets comprises of:

- (i) Customer related intangible arose from the Hospital and Medical Services Agreements which RHT Group entered into with the Sponsor, Fortis Healthcare Limited, to provide medical and Clinical Establishment services.
- (ii) Rights to use "Fortis" brand The two Operating Hospitals owned by RHT Group will continue to use the "Fortis" brand name for a period of 15 years from the date of transfer.
- (iii) Goodwill Goodwill mainly arose from the recognition of the deferred tax liability, being the difference between the tax effect of the value of acquired assets and liabilities and their respective tax bases. The balance of goodwill comprises the value of synergies arising from acquisition.

The decrease is due to the translation loss on account of depreciation of INR against SGD and the amortisation for the period.

2. Property, plant and equipment

Property, plant and equipment comprise of the land and building, plant and machinery, medical equipment and other assets of the Clinical Establishment and the 2 Operating Hospitals.

The decrease in property, plant and equipment is due to the translation loss on account of depreciation of INR against SGD and depreciation of property, plant and equipment for the period.

3. Financial assets

The non-current financial assets mainly relate to accrued income on straight-lining of the base service fee and security deposits paid. The increase is due to the recognition of accrued income on straight-lining of base service fee for the period.

The current financial assets mainly relate to investment in unquoted compulsory convertible preference shares (CCPS) of a related party, investment in quoted mutual funds and fixed deposits. The decrease is mainly due to the sale of quoted mutual funds made during the period and impact of the depreciation of INR against SGD.

4. Deferred tax assets

Deferred tax assets are made up of minimum alternate tax (MAT) credit paid to the India tax authorities. If the tax liability computed under the normal provisions of the India Income Tax Act is less than 18.5% of the book profits shown in the profit or loss account, after making certain specified adjustments, an entity is to pay minimum alternate tax at a rate of 18.5% of the book profits. MAT paid during the financial year is creditable for a period of 10 years against future tax liabilities arising under the normal provisions of the India Income Tax Act.

The decrease is due to utilisation of MAT credit for the corporate tax expense assessed in an India subsidiary.

5. Other non-current assets

Other non-current assets comprise of prepaid taxes deducted at source on service fee, hospital income and interest income on intra company debt instrument.

The increase is due to tax deducted at source on service fee for the period.

6. Trade receivables

Trade receivables comprise of service fees receivable from the Operators, rent receivables and receivables from corporate clients of the 2 operating hospitals.

The decrease is due to receipt of receivables during the quarter offset by the recognition of receivables for the quarter.



1(b)(i) Balance Sheets (Cont'd)

Notes to Balance Sheets (Cont'd)

7. Deferred tax liabilities

The deferred tax liabilities arose from the fair value adjustments arising on acquisition of subsidiaries at time of Initial Public Offering, revaluation of land, differences in depreciation and accrued income for tax purpose. The decrease is mainly due to reversal of deferred tax liability and depreciation of INR against SGD.

8. Other liabilities

Other non-current liabilities comprise mainly of retention amounts owing to creditors (capital in nature) as a result of ongoing capital expenditure for expansion and upgrading projects. The decrease is mainly due to some of these retention amounts becoming current.

Other current liabilities comprise of amount due to a related party for the purchase of 51% interest in FHTL, statutory dues and other creditors. The increase is mainly due to increase in advances from Fortis offset by payment of statutory dues and depreciation of INR against SGD.

9. Derivative financial instruments

RHT Group has entered into forward contracts to hedge its Indian Rupees denominated cash flows from India. The forward contracts are carried at fair value.

10. Capital reserve

The capital reserve represents the excess of interest of associates in the fair value of the net identifiable assets and liabilities transferred over the consideration paid. This reserve in substance represents the Sponsor's contribution to the Group for the Sponsor's retained interest. Please refer to page A-9 of the Prospectus dated 15 October 2012 for more details.

11. Other reserves

Other reserves comprise of:

- (i) Capital redemption reserve is a statutory reserve created in accordance with India's Companies Act 2013 in connection to redemption of preference shares of an India subsidiary company. The reserve is not considered a free reserve for distribution of dividend and can be utilised only for the purpose of issuing bonus shares.
- (ii) Re-measurement of defined benefit plan reserve is a reserve to record the actuarial gain or loss under a defined benefit plan which is recorded in other comprehensive income.



1(b)(ii) Group's Borrowings and Debt Securities

Amount Repayable in One Year or Less, or on Demand Amount Repayable after One Year

30 June 2016					
Secured	Unsecured				
S\$'000	S\$'000				
65,549	1,200				
41,499	63,355				

31 March 2016					
Secured	Unsecured				
S\$'000	S\$'000				
2,913	525				
103,312	63,407				

Details of Collateral

Singapore

Secured

The Group has loan facilities with DBS Bank Ltd and Deutsche Bank AG, Singapore Branch for an amount of \$\$32.5 million from each of the bank, in connection with the acquisition of Mohali Clinical Establishment.

In the third quarter of last financial year, the Group fully utilised a S\$30 million facility with United Overseas Bank for the acquisition of land and expansion projects.

Each term loan facility is secured by an irrevocable pledge on the shares of Fortis Global Healthcare Infrastructure Pte Ltd ("FGHIPL") on a pari passu basis, a non-disposal undertaking on the hospital infrastructure companies owned by FGHIPL on a pari passu basis and a first pari passu legal assignment over the interest, benefits and rights over all existing and future loans granted by the borrower to its subsidiaries.

The amount of unamortised upfront fees as of 30 June 2016 and 31 March 2016 are S\$ 1.26 million and S\$ 1.74 million respectively.

Unsecured

On 22 July 2015, the Trustee-Manager issued a \$\$60 million 4.50% fixed rate notes due and payable semiannually in arrears and will mature on 22 July 2018. The notes constitute direct, unconditional, unsubordinated and unsecured obligations of the RHT Health Trust and at all times rank pari passu and rateably, without any preference or priority amount themselves, and pari passu with all other present and future secured obligations (other than subordinated obligations and priorities created by law) of RHT Health Trust.

India

Secured

The India subsidiary companies have loans amounting to INR 121.6 million (S\$2.4 million) secured against assets purchased from the lender for which INR 45.9 million (S\$0.9 million) is repayable in one year or less.

The Group had entered into two INR term loan facilities with Axis Bank Limited. Each of the term loans are secured by BG Road and Ludhiana Clinical Establishment respectively and a legal assignment over the interest, benefits and rights over all existing and future loans granted by the borrower to its subsidiaries. The amount utilised as of 30 June 2016 is INR 509.8 million (S\$10.2 million).

Unsecured

The Group has received an unsecured and interest-free loan amounting to INR 168.3 million (S\$3.4 million) from the Sponsor for the development of Ludhiana Greenfield Clinical Establishment. This loan is repayable on the completion of the Ludhiana Greenfield Clinical Establishment.



Group

1(c) Consolidated Cash Flow Statement

Net Profit before tax 15,449 FY 16 Q1 S\$000 Adjustments for: 15,449 16,426 Depreciation and amortisation expense 3,869 3,891 Finance income (441) (1(36) Finance expenses 2,333 1,442 Unrealised gain on financial assets (3) (3) Foreign exchange loss 2,365 (231) (5,340) Foreign currency alignment 464 (496)		0.00	~P
Adjustments for: a,869 3,891 Depreciation and amortisation expense 3,869 3,891 Finance income (441) (136) Finance expenses 2,333 1,442 Unrealised gain on financial assets (3) (3) Fair value gain on financial derivatives (231) (5,340) Foreign exchange loss - 2,965 Foreign currency alignment 464 (496) Operating cash flow before working capital changes 21,440 18,749 Changes in working capital: 0 13,899 19,888 Increase in financial assets and other assets (1,595) (2,793) Decrease in inventories 1 1,595) (2,793) Increase in trade and other payables and other liabilities 12,143 8,092 Cash flows generated from operations 45,887 43,945 Interest received 441 133 Tax paid (9,677) (8,322) Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities		i i	
Adjustments for: a,869 3,891 Depreciation and amortisation expense 3,869 3,891 Finance income (441) (136) Finance expenses 2,333 1,442 Unrealised gain on financial assets (3) (3) Fair value gain on financial derivatives (231) (5,340) Foreign exchange loss - 2,965 Foreign currency alignment 464 (496) Operating cash flow before working capital changes 21,440 18,749 Changes in working capital: 0 13,899 19,888 Increase in financial assets and other assets (1,595) (2,793) Decrease in inventories 1 1,595) (2,793) Increase in trade and other payables and other liabilities 12,143 8,092 Cash flows generated from operations 45,887 43,945 Interest received 441 133 Tax paid (9,677) (8,322) Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities	Net Profit before tax	15,449	16,426
Depreciation and amortisation expense 3,869 3,891 Finance income (441) (136) Finance expenses 2,333 1,442 Unrealised gain on financial assets (3) (3) Fair value gain on financial derivatives (231) (5,340) Foreign exchange loss - 2,965 Foreign currency alignment 464 (496) Operating cash flow before working capital: 21,440 18,749 Changes in working capital: 13,899 19,888 Increase in trade receivables 13,899 19,888 Increase in trade and other assets (1,595) (2,793) Decrease in inventories - 9 Increase in trade and other payables and other liabilities 12,143 8,092 Cash flows generated from operations 45,887 43,945 Interest received 441 133 Tax paid (9,677) (8,322) Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities (3,235) (2,234)	Adjustments for:	'	,
Finance income (441) (136) Finance expenses 2,333 1,442 Unrealised gain on financial assets (3) (3) Fair value gain on financial derivatives (231) (5,340) Foreign exchange loss - 2,965 Foreign currency alignment 464 (496) Operating cash flow before working capital changes 21,440 18,749 Changes in working capital: 21,440 18,749 Decrease in trade receivables 13,899 19,888 Increase in financial assets and other assets (1,595) (2,793) Decrease in inventories - 9 Increase in trade and other payables and other liabilities 12,143 8,092 Cash flows generated from operations 45,887 43,945 Interest received 441 133 Tax paid (9,677) (8,322) Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities (3,235) (2,234) Sale/(investment) in short term investments 616 (1,		3.869	3.891
Finance expenses	·		· ·
Unrealised gain on financial assets (3) (3) Fair value gain on financial derivatives (231) (5,340) Foreign exchange loss - 2,965 Foreign currency alignment 464 (496) Operating cash flow before working capital changes 21,440 18,749 Changes in working capital: 13,899 19,888 Increase in francial assets and other assets (1,595) (2,793) Decrease in inventories - 9 Increase in inventories - 9 Increase in trade and other payables and other liabilities 12,143 8,092 Cash flows generated from operations 45,887 43,945 Interest received 441 133 Interest received 441 133 Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities 36,651 35,756 Cash flow from investing activities (3,235) (2,234) Sale/(investment) in short term investments 616 (1,737) Net cash used in investing activities		, ,	` '
Fair value gain on financial derivatives (231) (5,340) Foreign exchange loss - 2,965 Foreign currency alignment 464 (496) Operating cash flow before working capital changes 21,440 18,749 Changes in working capital: - - Decrease in trade receivables 13,899 19,888 Increase in financial assets and other assets (1,595) (2,793) Decrease in inventories - 9 Increase in trade and other payables and other liabilities 12,143 8,092 Cash flows generated from operations 45,887 43,945 Interest received 441 133 Tax paid (9,677) (8,322) Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities (9,677) (8,322) Net cash used in investing activities (3,235) (2,234) Sale/(investment) in short term investments 616 (1,737) Net cash used in investing activities (2,619) (3,971) Cash flow from financing activi	·		
Foreign exchange loss - 2,965 Foreign currency alignment 464 (496) Operating cash flow before working capital changes 21,440 18,749 Changes in working capital: 21,889 19,888 Increase in trade receivables 13,899 19,888 Increase in inventories - 9 Increase in trade and other payables and other liabilities 12,143 8,092 Cash flows generated from operations 45,887 43,945 Interest received 441 133 Tax paid (9,677) (8,322) Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities (9,677) (8,322) Purchase of property, plant and equipment (3,235) (2,234) Sale/(investment) in short term investments 616 (1,737) Net cash used in investing activities (2,619) (3,971) Cash flow from financing activities (30,478) (29,481) Interest paid (2,673) (2,066) Net cash generated used in financing activities <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td>	· · · · · · · · · · · · · · · · · · ·		
Operating cash flow before working capital changes 21,440 18,749 Changes in working capital: 13,899 19,888 Increase in frade receivables (1,595) (2,793) Increase in financial assets and other assets (1,595) (2,793) Decrease in inventories - 9 Increase in trade and other payables and other liabilities 12,143 8,092 Cash flows generated from operations 45,887 43,945 Interest received 441 133 Tax paid (9,677) (8,322) Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities (3,235) (2,234) Purchase of property, plant and equipment (3,235) (2,234) Sale/(investment) in short term investments 616 (1,737) Net cash used in investing activities (2,619) (3,971) Cash flow from financing activities (30,478) (29,481) Distribution paid to unitholders (30,478) (29,481) Interest paid (2,673) (2,066) Ne	-	- 1	2,965
Changes in working capital: 13,899 19,888 Increase in trade receivables (1,595) (2,793) Decrease in financial assets and other assets (1,595) (2,793) Decrease in inventories - 9 Increase in trade and other payables and other liabilities 12,143 8,092 Cash flows generated from operations 45,887 43,945 Interest received 441 133 Tax paid (9,677) (8,322) Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities (9,677) (8,322) Purchase of property, plant and equipment (3,235) (2,234) Sale/(investment) in short term investments 616 (1,737) Net cash used in investing activities (2,619) (3,971) Cash flow from financing activities (30,478) (29,481) Distribution paid to unitholders (30,478) (29,481) Interest paid (2,673) (2,066) Net proceeds from borrowings 2,256 3,699 Net cash generated used in	Foreign currency alignment	464	(496)
Decrease in trade receivables 13,899 19,888 Increase in financial assets and other assets (1,595) (2,793) Decrease in inventories - 9 Increase in trade and other payables and other liabilities 12,143 8,092 Cash flows generated from operations 45,887 43,945 Interest received 441 133 Tax paid (9,677) (8,322) Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities (2,234) Purchase of property, plant and equipment (3,235) (2,234) Sale/(investment) in short term investments 616 (1,737) Net cash used in investing activities (2,619) (3,971) Cash flow from financing activities (2,619) (3,971) Cash flow from financing activities (2,673) (2,066) Net proceeds from borrowings 2,256 3,699 Net cash generated used in financing activities (30,895) (27,848) Net increase in cash and cash equivalents 3,137 3,937 Cash a	Operating cash flow before working capital changes	21,440	18,749
Increase in financial assets and other assets	Changes in working capital:		
Decrease in inventories 1- 9 Increase in trade and other payables and other liabilities 12,143 8,092 Cash flows generated from operations 45,887 43,945 Interest received 441 133 Tax paid (9,677) (8,322) Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities 2 Purchase of property, plant and equipment (3,235) (2,234) Sale/(investment) in short term investments 616 (1,737) Net cash used in investing activities (2,619) (3,971) Cash flow from financing activities (30,478) (29,481) Interest paid (2,673) (2,066) Net proceeds from borrowings (30,895) (27,848) Net increase in cash and cash equivalents 3,137 3,937 Cash and cash equivalent at beginning of period 5,831 4,170	Decrease in trade receivables	13,899	19,888
Increase in trade and other payables and other liabilities	Increase in financial assets and other assets	(1,595)	(2,793)
Cash flows generated from operations 45,887 43,945 Interest received 441 133 Tax paid (9,677) (8,322) Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities (3,235) (2,234) Purchase of property, plant and equipment (3,235) (2,234) Sale/(investment) in short term investments 616 (1,737) Net cash used in investing activities (2,619) (3,971) Cash flow from financing activities (30,478) (29,481) Distribution paid to unitholders (30,478) (29,481) Interest paid (2,673) (2,066) Net proceeds from borrowings 2,256 3,699 Net cash generated used in financing activities (30,895) (27,848) Net increase in cash and cash equivalents 3,137 3,937 Cash and cash equivalent at beginning of period 5,831 4,170	Decrease in inventories	-	9
Interest received 441 133 Tax paid (9,677) (8,322) Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities 2 Purchase of property, plant and equipment (3,235) (2,234) Sale/(investment) in short term investments 616 (1,737) Net cash used in investing activities (2,619) (3,971) Cash flow from financing activities (30,478) (29,481) Interest paid (2,673) (2,066) Net proceeds from borrowings 2,256 3,699 Net cash generated used in financing activities (30,895) (27,848) Net increase in cash and cash equivalents 3,137 3,937 Cash and cash equivalent at beginning of period 5,831 4,170	Increase in trade and other payables and other liabilities	12,143	8,092
Interest received 441 133 Tax paid (9,677) (8,322) Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities 2 Purchase of property, plant and equipment (3,235) (2,234) Sale/(investment) in short term investments 616 (1,737) Net cash used in investing activities (2,619) (3,971) Cash flow from financing activities (30,478) (29,481) Interest paid (2,673) (2,066) Net proceeds from borrowings 2,256 3,699 Net cash generated used in financing activities (30,895) (27,848) Net increase in cash and cash equivalents 3,137 3,937 Cash and cash equivalent at beginning of period 5,831 4,170			
Tax paid (9,677) (8,322) Net cash generated from operating activities 36,651 35,756 Cash flow from investing activities	Cash flows generated from operations	45,887	43,945
Net cash generated from operating activities36,65135,756Cash flow from investing activities(3,235)(2,234)Purchase of property, plant and equipment(3,235)(2,234)Sale/(investment) in short term investments616(1,737)Net cash used in investing activities(2,619)(3,971)Cash flow from financing activities(30,478)(29,481)Distribution paid to unitholders(2,673)(2,066)Net proceeds from borrowings2,2563,699Net cash generated used in financing activities(30,895)(27,848)Net increase in cash and cash equivalents3,1373,937Cash and cash equivalent at beginning of period5,8314,170	Interest received	441	133
Cash flow from investing activities(3,235)(2,234)Purchase of property, plant and equipment(3,235)(2,234)Sale/(investment) in short term investments616(1,737)Net cash used in investing activities(2,619)(3,971)Cash flow from financing activities(30,478)(29,481)Interest paid(2,673)(2,066)Net proceeds from borrowings2,2563,699Net cash generated used in financing activities(30,895)(27,848)Net increase in cash and cash equivalents3,1373,937Cash and cash equivalent at beginning of period5,8314,170	Tax paid	(9,677)	(8,322)
Purchase of property, plant and equipment (3,235) (2,234) Sale/(investment) in short term investments 616 (1,737) Net cash used in investing activities (2,619) (3,971) Cash flow from financing activities (30,478) (29,481) Interest paid (2,673) (2,066) Net proceeds from borrowings 2,256 3,699 Net cash generated used in financing activities (30,895) (27,848) Net increase in cash and cash equivalents 3,137 3,937 Cash and cash equivalent at beginning of period 5,831 4,170	Net cash generated from operating activities	36,651	35,756
Sale/(investment) in short term investments 616 (1,737) Net cash used in investing activities (2,619) (3,971) Cash flow from financing activities (30,478) (29,481) Distribution paid to unitholders (2,673) (2,066) Net proceeds from borrowings 2,256 3,699 Net cash generated used in financing activities (30,895) (27,848) Net increase in cash and cash equivalents 3,137 3,937 Cash and cash equivalent at beginning of period 5,831 4,170	Cash flow from investing activities		
Net cash used in investing activities(2,619)(3,971)Cash flow from financing activities(30,478)(29,481)Distribution paid to unitholders(2,673)(2,066)Net proceeds from borrowings2,2563,699Net cash generated used in financing activities(30,895)(27,848)Net increase in cash and cash equivalents3,1373,937Cash and cash equivalent at beginning of period5,8314,170	Purchase of property, plant and equipment	(3,235)	(2,234)
Cash flow from financing activities(30,478)(29,481)Distribution paid to unitholders(2,673)(2,066)Interest paid(2,673)(2,066)Net proceeds from borrowings2,2563,699Net cash generated used in financing activities(30,895)(27,848)Net increase in cash and cash equivalents3,1373,937Cash and cash equivalent at beginning of period5,8314,170	Sale/(investment) in short term investments	616	(1,737)
Distribution paid to unitholders (30,478) (29,481) Interest paid (2,673) (2,066) Net proceeds from borrowings 2,256 3,699 Net cash generated used in financing activities (30,895) (27,848) Net increase in cash and cash equivalents 3,137 3,937 Cash and cash equivalent at beginning of period 5,831 4,170	Net cash used in investing activities	(2,619)	(3,971)
Distribution paid to unitholders (30,478) (29,481) Interest paid (2,673) (2,066) Net proceeds from borrowings 2,256 3,699 Net cash generated used in financing activities (30,895) (27,848) Net increase in cash and cash equivalents 3,137 3,937 Cash and cash equivalent at beginning of period 5,831 4,170	Cash flow from financing activities		
Interest paid (2,673) (2,066) Net proceeds from borrowings 2,256 3,699 Net cash generated used in financing activities (30,895) (27,848) Net increase in cash and cash equivalents 3,137 3,937 Cash and cash equivalent at beginning of period 5,831 4,170		(30,478)	(29,481)
Net cash generated used in financing activities(30,895)(27,848)Net increase in cash and cash equivalents3,1373,937Cash and cash equivalent at beginning of period5,8314,170	Interest paid	(2,673)	
Net increase in cash and cash equivalents3,1373,937Cash and cash equivalent at beginning of period5,8314,170	Net proceeds from borrowings		
Cash and cash equivalent at beginning of period 5,831 4,170	Net cash generated used in financing activities	(30,895)	(27,848)
	Net increase in cash and cash equivalents	3,137	3,937
Cash and cash equivalents at end of period 8,968 8,107	Cash and cash equivalent at beginning of period	5,831	4,170
	Cash and cash equivalents at end of period	8,968	8,107



1(d)(i) Statement of Changes in Unitholders' Funds

<u>Group S\$'000</u> At 1 April 2016	Units in issue (net of units issue cost) 510,399	Capital reserve 210,216	Foreign currency translation reserve (82,469)	Revaluation reserve 142,911	Capital redemption reserve 33	(Accumulated losses)/ Revenue reserves (41,482)	Total 739,608
Profit for the period						10,666	10,666
Other comprehensive income			(10.570)				(40.570)
Foreign currency translation			(16,578)				(16,578)
Depreciation transfer for land and building				(1,740)		1,740	
Total comprehensive income	-	-	(16,578)	(1,740)	-	12,406	(5,912)
Payment of Trustee-Manager fees in units	1,658					(00.470)	1,658
Distribution on units in issue						(30,478)	(30,478)
At 30 June 2016	512,057	210,216	(99,047)	141,171	33	(59,554)	704,876
<u>Group S\$'000</u> At 1 April 2015	Units in issue (net of units issue cost) 507,180	Capital reserve 210,216	Foreign currency translation reserve (23,854)	Revaluation reserve 101,396	Capital redemption reserve 69	(Accumulated losses)/ Revenue reserves (25,874)	Total 769,133
Profit for the period						12,295	12,295
Other comprehensive income			(04.000)				(04 000)
Foreign currency translation	-	-	(31,366)	-	-	-	(31,366)
Net surplus revaluation of land and buildings		-	-	(793)	-	793	
Total comprehensive income	-	-	(31,366)	(793)	-	13,088	(19,071)
Payment of Trustee-Manager fees in units	1,582	_	-	-	-	-	1,582
Distribution on units in issue	=	-	_	-	-	(29,482)	(29,482)



1(d)(i) Statement of Changes in Unitholders' Funds (Cont'd)

Trust At 1 April 2016

Loss for the period, representing total comprehensive income for the period

Payment of Trustee-Manager fees in units Distribution on units in issue

At 30 June 2016

	Revenue reserves/	R
	(Accumulated	Units in issue (net
Total	losses)	of unit issue cost)
S\$'000	S\$'000	S\$'000
477,427	(32,972)	510,399
(12,044)	(12,044)	-
1,658 (30,478)	(30,478)	1,658
436.563	(75.494)	512.057

Trust At 1 April 2015

Loss for the period, representing total comprehensive income for the period

Payment of Trustee-Manager fees in units Distribution on units in issue

At 30 June 2015

	Revenue	
Units in issue	reserves/	
(net of unit	(Accum ulated	
issue cost)	losses)	Total
S\$'000	S\$'000	S\$'000
507,180	14,427	521,607
-	(19,001)	(19,001)
1,582 -	- (29,481)	1,582 (29,481)
508,762	(34,055)	474,707



1(d)(ii) Units in issue

Balance as at 1 April

Issue of new units

- Payment of Trustee-Manager fees in units

Balance as at 30 June

FY	17
Number of	
units	
'000	S\$'000
797,842	510,399
1,753	1,658
799,595	512,057

FY 16				
Number of				
units				
'000	S\$'000			
794,633	507,180			
1,542	1,582			
796,175	508,762			

2 Audit

The figures in this announcement have not been audited or reviewed by our auditor.

3 Auditors' Report

Not applicable.

4 Accounting Policies

The Group has applied the same accounting policies and methods of computation as in the Group's 31 March 2016 annual financial statement dated 24 June 2016 except for the adoption of all new and revised IFRS that are effective for annual periods beginning 1 April 206. The changes in accounting standards do not have a material impact to the Group and its financial statements.

5 Changes in Accounting Policies

There is no change in the accounting policies and methods of computation adopted except as mentioned above.



6 Earnings Per Unit ("EPU") and Distribution Per Unit ("DPU")

	Group		
	FY 17 Q1	FY 16 Q1	
Weighted number of units	798,015,318	794,751,559	
Total units	799,594,944	796,174,944	
EPU (cents)			
Net profit	10,666	12,295	
Based on weighted number of units as at 30 June	1.337	1.547	
DPU based on income available for distribution (cents)			
Distributable income	15,134	15,443	
Distribution	14,377	15,443	
Based on total units as at 30 June	1.798	1.940	

Diluted EPU is the same as the basic EPU as there were no dilutive instruments in issue during the financial period.

The DPU for the current quarter is lower due to the corporate tax expense in an India subsidiary despite the higher Net Service Fee and Hospital Income. Please see paragraph 8 for more details. In addition, management intends to distribute 95% of the distributable income for the current financial year, hence resulting the DPU to drop even lower compared to corresponding quarter.

The DPU provided is for illustration purpose only. Please see paragraph 11 for information on distribution to unitholders.

7 Net Asset Value

NAV No. of units in issue at end of period NAV per unit (S\$)

Group				
30 June 2016 31 March 2016				
704,876,000	739,608,000			
799,594,944	797,841,944			
0.882	0.927			

The decrease in NAV per unit by around 5% is due to the distribution to unitholders (amounting to 4%) and balance due to translation loss on account of depreciation of INR against SGD (1%) during the period.



8 Review of Group Performance

Quarter analysis

	Group						
	FY 17 Q1	FY 16 Q4	Variance		FY 16 Q1	Variance	
	S\$'000	S\$'000	S\$'000	%	S\$'000	S\$'000	%
Total Revenue (excluding straight		-	•		·		
lining)	34,537	33,817	720	2.1%	34,257	280	0.8%
Net Service Fee and Hospital Income (excluding straight-lining, depreciation and amortisation)	22,859	23,272	(413)	-1.8%	22,853	6	0.0%
Margin	66%	69%			67%		
Distributable Income	15,134	15,261	(127)	-0.8%	15,443	(309)	-2.0%
	INR'000	INR'000	INR'000	%	INR'000	INR'000	%
Total Revenue (excluding straight lining) Net Service Fee and Hospital	1,707,551	1,641,315	66,236	4.0%	1,626,672	80,879	5.0%
Income (excluding straight-lining, depreciation and amortisation) (A)	1,130,187	1,128,897	1,290	0.1%	1,085,157	45,030	4.1%

FY 17 Q1 against FY 16 Q4

Exchange rate

The foreign exchange rates used to translate the results of the India subsidiary companies are INR/SGD 49.44 and INR/SGD 48.50 for the quarter 30 June 2016 and 31 March 2016 respectively.

Total Revenue

Total Revenue for FY 17 Q1 in INR terms increased by 4.0% from FY 16 Q4 mainly due to the contractual increase in base fee and higher variable fee as a result of higher operating revenue recorded by Fortis. The higher operating revenue of Fortis was a result of higher occupancy and higher ARPOB contributed by the increase in major surgeries such as heart and liver transplant, joint replacement and neuro.

Net Service Fee and Hospital Income (excluding straight-lining, depreciation and amortisation)

Net Service Fee and Hospital Income (excluding straight-lining, depreciation and amortisation) in INR terms is similar to the trailing quarter despite the increase in revenue. This is due to the

- (i) corresponding increase in variable expenses such as doctors' charges and medical consumables;
- (ii) increase in personnel cost arising from the additional headcount for the project team and respective clinical establishment; and
- (iii) increase in housekeeping and security cost arising from inflationary increase and increased activities.

The year to date margin of last year was 67.6%. The lower margin of 66.2% this quarter was due to inflationary increase of fixed cost such as housekeeping and security cost which was higher than the increase in revenue. Management will monitor and work towards controlling such cost increases.

Distributable Income

Despite the improved revenue and improved contracted forward rates of INR/SGD 49.35 compared to 49.59 in the trailing quarter, Distributable income was lower due to corporate tax amounting to INR 59 million in one of the India subsidiary and higher operating expenses.



8 Review of Group Performance (Cont'd)

FY 17 Q1 against FY 16 Q1

Exchange rate

The foreign exchange rates used to translate the results of the India subsidiary companies are SGD/INR 49.44 and SGD/INR 47.48 for the guarter 30 June 2016 and 30 June 2015 respectively.

Total Revenue

Total Revenue for FY 17 Q1 in INR terms grew 5.0% from FY 16 Q1 mainly due to the contractual increase in base fee, higher variable fee as a result of higher operating revenue recorded by Fortis (accounting for 3% of the 5.0%). The higher operating revenue of Fortis was a result of higher occupancy and higher ARPOB contributed by the increase in major surgeries such as heart and liver transplant, joint replacement and neuro

Net Service Fee and Hospital Income (excluding straight-lining, depreciation and amortisation)

Net Service Fee and Hospital Income (excluding straight-lining, depreciation and amortisation) increased by 4.1% in INR terms due to increase in total revenue. However, margins was slightly lower compared to corresponding quarter by 1% as a result of inflationary increase of fixed cost such as housekeeping and security cost which was higher than the increase in revenue. Management will monitor and work towards controlling such cost increases.

Distributable Income

Despite higher Net Service Fee and Hospital Income, the Distributable Income was lower largely due to an increase in corporate tax in India and higher finance cost in the current quarter.

9 Variance from Forecast

No forecast has been provided.

10 Market and Industry Information

The Indian healthcare industry presents both opportunities and challenges. The potential room for growth in the industry is attractive, with the country's large, expanding and increasingly affluent population requiring more sophisticated and better medical services. In the near term, the increasing and aging population and rising affluence, coupled with the shortage of healthcare infrastructure in India, are expected to be the immediate drivers of growth for the industry. We expect the private sector to play a key role in filling the demand for these medical services. At the same time, the potential for growth in the industry leads to increasing competition from new entrants. RHT will continue to look at expanding the portfolio both organically and inorganically.

At the Extraordinary General Meeting held on 29 July 2016, Unitholders had approved the proposed disposal of 51% of compulsorily convertible debentures held in Fortis Hospotel Limited ("FHTL") and 100% of compulsorily convertible preference shares held in Escorts Heart Institute and Research Centre Limited (the "Disposal") to, as well as the Related Arrangements with, interested persons¹. Upon completion of the Disposal, control over FHTL will be transferred to FHIL and accordingly the Group will recognise FHTL as an associate instead of a subsidiary. Information on the special distribution to be paid out from the proceeds of the Disposal will be also announced in due course.

11 Information on Distribution

Current financial period

No.

Corresponding period of the immediately preceding year

No.

¹ Fortis Healthcare International Limited, Fortis Healthcare Limited and Fortis Hospitals Limited



12 Distribution

Please refer to paragraph 11.

13 Interested Person Transactions

The Group has not obtained any interested person transactions mandate from the Unitholders.

14. Confirmation by Board

The Board of Directors of RHT Health Trust Manager Pte. Ltd. has confirmed that, to the best of their knowledge, nothing has come to their attention which may render these interim financial results to be false or misleading in any material aspect.

15. Confirmation by Issuer

The issuer has procured undertakings from all its directors and executive officers under Rule 720(1).

Disclaimer:

This release may contain forward-looking statements that involve risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. You are cautioned not to place undue reliance on these forward looking statements, which are based on current view of management on future events.

By Order of the Board RHT Health Trust Manager Pte. Ltd.

Gurpreet Singh Dhillon Executive Director & Chief Executive Officer 3 August 2016